

## KEY COMPANY DATA

Current Stock Price	\$0.007
Target Price	\$0.04+
% Upside	450%
Market Cap	\$2.1 million
Business	Psychedelics, mental health
Shares Outstanding	315 million
Float	
Stock Exchange	OTC
SEC Reporting	Yes (1-A)

## STOCK PERFORMANCE

1 Month	00.00%
3 Months	00.00%
6 Months	00.00%
12 Months	00.00%

## COMPANY INFO

**CEO:** Benjamin Kaplan

**Ehave, Inc.**  
100 SE 2nd St. Suite 2000  
Miami, FL 33131

**Telephone:** (954) 233-3511

**Email:** ir@ehave.com

**Website:** [www.ehave.com](http://www.ehave.com)

**Twitter:** @Ehaveinc1

**LinkedIn:** [linkedin.com/company/ehave/](https://www.linkedin.com/company/ehave/)

## COMPANY OPERATIONS

Ehave is a leading healthcare services and technology company, focused on progressing psychedelics-to-Therapeutics by engineering novel compounds and new treatment protocols for treating brain health. Together with our network of scientists and mental health professionals, we are on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues, leveraging clinical data to help us achieve optimal patient outcomes. Ehave's operations span across the entire USA, Canada, Jamaica, and Australia. Additional information on Ehave can be found on the Company's website at: [www.ehave.com](http://www.ehave.com)

## INVESTOR HIGHLIGHTS

- **Mobile Ketamine treatment service.** KetaDASH offers ketamine for treatment resistant depression, anxiety, PTSD, and other conditions. After a short telemedicine visit, an experienced nurse will arrive at your location of choice to administer the sublingual treatment. [www.ketadash.com](http://www.ketadash.com)
- **Psychedelics Genetic Testing.** Help identify how an individual's DNA profile can affect their response to hallucinogenic drugs. The information contained in this report is based on research related to specific genetic polymorphisms and their influence on pharmacodynamics, pharmacokinetics and mental health risk factors for psychedelics use.
- **AI Powered Mental Health Apps.** Continuous and reliable data is the missing key needed to create personalized care. Show your care through our mobile-first solution, backed by science and created for mental health analysis and monitoring, mood and emotions tracking through vocal biomarkers [www.metahealthu.com](http://www.metahealthu.com)
- **Stake in Pending PSLY.COM Merger.** Mycotopia Therapies and Ei.Ventures will be structured to form PSLY.COM, and operate as subsidiaries after the merger. PSLY.COM will apply for a NASDAQ listing. Mycotopia Therapies primary focus is on mushroom and psychedelic opportunities. [www.mycotopiatherapies.com](http://www.mycotopiatherapies.com)

## RESEARCH SUMMERY

As economies across the globe emerging from pandemic restrictions many individuals are facing increased mental health stress from economic factors such as inflation, and possible recession.

For many individuals who made it through the pandemic, the prospects of increased economic stress so soon after reopening could present a catalyst for potential Mental Health Crisis in the United States, and Europe.

Increases in mental health disorders, such as anxiety, depression, and post-traumatic stress disorder (PTSD), may result in increased demand for alternative mental health treatments such as psychedelics, which could increase the outlook for Ehave operations in 2023.

Ehave holds a sizeable equity stake in pending TPIA merger, where Ei.Ventures and PSLY.COM will merger into **Mycotopia Therapies** (OTC:TPIA), and potentially up list to NASDAQ exchange.

For these reasons, Ludlow Research has initiated coverage on Ehave, Inc. (OTC:EHVVF) with a 'speculative' short-term target of **\$0.04 per share**.

Ludlow Research also issued research opinion on Mycotopia Therapies Inc. (OTC:TPIA), based on potential NASDAQ up listing merger with Ei.Ventures, with a 'speculative' short-term target of **\$2.00+ per share**.



### KetaDASH, Mobile Ketamine Treatment

KetaDASH Mobile Unit is specifically designed to focus on safety, setting, comfort and efficacy of treatments. This innovative service departs from in-clinic intravenous, treatment or unsupervised telehealth models to an at-home ketamine administration with telehealth and in-person medical supervision. A typical KetaDASH experience incorporates a prescribing doctor, a nurse for administration and monitoring, and psychotherapists for integration, all from the comfort of the patient's home. Follow KetaDASH on Instagram at [www.instagram.com/ketadash.usa](https://www.instagram.com/ketadash.usa)



## GENETIC TESTING PROFILE FOR PSYCHEDELIC TREATMENT

HaluGen Psychedelics Genetic Test is a pharmacogenomic test to help identify how an individual's DNA profile can affect their response to hallucinogenic drugs. The information contained in this report is based on research related to specific genetic polymorphisms and their influence on pharmacodynamics, pharmacokinetics and mental health risk factors for psychedelics use.

Ehave announced a partnership with Enttheon Biomedical Corp.'s (CSE: ENBI) (OTCQB: ENTBF) HaluGen Life Sciences Inc. to use its psychedelics genetic test kit. KetaDASH will become one of the first psychedelic companies to use precision medicine to test patients by using HaluGen's expanded psychedelics genetic testing panel, which analyzes a series of relevant DNA biomarkers and utilizes pre-screening mental health surveys in order to provide insights into an individual's risk and potential of adverse reactions with the use of ketamine.

### HTR2A GENE - SEROTONIN SENSITIVITY

Approximately 20% of people carry an HTR2A genetic variant which can increase serotonin receptor density, potentially making them more susceptible to stronger hallucinogenic effects. These individuals should be more cautious when considering classical psychedelic therapies.

### CYP2B6 GENE - KETAMINE METABOLISM

The way your body metabolizes ketamine, a fast-acting anesthetic with hallucinogenic properties, is influenced by the CYP2B6 gene. This gene encodes a liver enzyme that helps metabolize ketamine in your bloodstream. 10–20% of people carry the CYP2B6\*6 genetic variant which causes them to metabolize ketamine up to 2x to 3x slower than normal.

### CYP2D6 GENE - LSD, MDMA & AYAHUASCA METABOLISM

The way your body metabolizes LSD, MDMA and ayahuasca, is influenced by the CYP2D6 gene. This gene encodes a liver enzyme that helps metabolize these drugs in your bloodstream. 5–10% of people carry the CYP2D6 genetic variant which causes them to metabolize LSD, MDMA and ayahuasca up to 2x slower than normal.

## Ehave, Inc. (OTC:TPIA)



### RECENT NEWS

June 03, 2022

**Ehave, Inc. Announces its KetaDASH Mobile Unit will be Delivered to Miami Beach on June 10, 2022**

June 01, 2022

**Ehave, Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research**

May 23, 2022

**Ehave Announces Mycotopia Therapies Reaches Definitive Agreement on Triangular Merger with Ei.Ventures to Form PSLY.com to List on NASDAQ**

Wednesday, April 20, 2022

**Ehave Inc. (Stock Symbol: EHVVF) Announces MetaHealthU Will Enter The Market With A Focus On HPPD**

## Mycotopia Therapies (OTC:TPIA)



### PENDING MERGER AND UP LISTING TO NASDAQ

Mycotopia Therapies (OTC: TPIA) has signed a definitive agreement to complete a triangular merger with Ei.Ventures, an early-stage tech company empowering mental wellness through psychoactive compounds, nutraceuticals and technology, to form PSLY.COM.

The transaction between Mycotopia Therapies and Ei.Ventures will be structured as a triangular merger. The two companies will form a new holding company, PSLY.COM, and operate as subsidiaries after the merger. PSLY.COM will apply for a NASDAQ listing.

Mycotopia Therapies primary focus is on mushroom and psychedelic opportunities. The company has been performing most of its research in Jamaica, where psilocybin is legal, as well as working with one of the largest cannabis labs in the Netherlands to develop psychedelics to jointly license certain molecules to be used in psychedelic medicine.

Ei.Ventures' ambition is to deliver governmental approved therapeutic treatment options that address the current global mental healthcare pandemic. By leveraging blockchain, emerging technologies and the Metaverse, Ei.Ventures intends to create a safe, efficient, and secure way to provide telehealth services in general, as well as for psychoactive therapeutics.

**Disclosures and Disclaimer:**

**THE MATERIAL HEREIN DOES NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY JURISDICTION WHERE OR TO ANY PERSON TO WHOM IT WOULD BE UNAUTHORIZED OR UNLAWFUL TO DO SO.**

The material herein is provided for informational purposes only and should not be construed as investment advice or an offer or solicitation to buy or sell securities.

This reports contains certain statements that may be deemed “forward-looking” statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by law, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

Ludlow Research (“Ludlow”), and its parent company Ludlow Consulting, LLC, are not registered broker-dealers or investment advisers with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”), or any state securities regulatory authority.

Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Ludlow does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. Ludlow, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encouraged to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Ludlow was compensated three thousand six hundred dollars for research report, and holds business relationships through affiliate company, and thus should be considered a conflict of interest when reviewing this information. Investments is speculative ‘penny stocks’, as defined by the SEC, may involve a high degree of risk.

**INVESTORS ARE HIGHLY ENCOURAGED TO CONSULT WITH A FINANCIAL ADVISOR BEFORE MAKING ANY AND ALL INVESTMENT DECISIONS.**

**AI Venturetech, Inc.**

Thomas Bustamante

Strategic Advisor

LinkedIn: [www.linkedin.com/in/tombustamante/](http://www.linkedin.com/in/tombustamante/)

**Ludlow Research**

Twitter: <https://twitter.com/ludlowresearch>

Website: [www.ludlowresearch.com](http://www.ludlowresearch.com)

Email: [info@ludlowresearch.com](mailto:info@ludlowresearch.com)

---